Merck Serono S. a.

Laboratories Serono Sa

Amprion, Inc.

Claudio Soto-Jara

Claudia Pena-Rossi

Benedikt K Vollrath

Russell M Lebovitz

Mohammad Shahnawaz

Nicolas Mendez Dinamarca

Kinsey Maundrell

Methods and kits are provided for amplifying and detecting misfolded tau protein from samples, for example, from patients having tauopathies such as Alzheimer's Disease, Progressive Supranuclear Palsy, and the like.

Detection of misfolded tau protein

The present invention discloses peptides isolated from the extracellular domain of OX40 Ligand (OX40L) capable of binding OX40 Receptor (OX40R) and inhibiting OX40R-OX40L interaction. Such peptides, fusion proteins comprising them, as well as peptides and other molecules designed on their sequences, can be used as OX40R binding agents competing with natural OX40L for blocking OX40R-mediated cell signaling in the prophylaxis and/or treatment of diseases related to activated T cells.

OX40R binding agents

The use of Apolipoprotein B, Apolipoprotein E, fragments and mimetics thereof is provided for diagnostic, detection, prognostic and therapeutic applications In prion diseases. More specifically, the invention provides the use of Apolipoprotein B or fragments thereof for modulating or identifying modulators of the prion protein replication which are implicated in the pathogenesis of transmissible spongiform encephalopathics and other prion diseases.

Use of prion conversion modulating agents

Growing community of inventors

Friendswood, TX, United States of America

Claudio Soto-Jara